Trial Profile

Safety and Efficiency Study of ET019003-T Cells in Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ET 019003 (Primary) ; Cyclophosphamide; Fludarabine
Indications B-cell lymphoma; CNS cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man

Most Recent Events

14 Dec 2021 Results (n=8) assessing the outcomes for adult patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) treated with ET019003-T cells, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
04 Nov 2021 Planned number of patients changed from 18 to 9.
04 Nov 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com